Blind submission and why it changes minds — the long version

Posting this under the heading it deserves: Blind submission and why it changes minds — the long version Everything below is what sits behind that.

Structured report rather than an opinion, following the format the maintainers asked for.

• Compound: retatrutide
• Independent testing: Medutest
• Method as reported: reversed-phase HPLC, 280 nm
• Result: 96.4% area
• Certificate figure for the same lot: 98.1%

I am not drawing a conclusion about the supplier from one lot and I would ask that nobody else does either. I am adding a data point to a record.

On the opening post — agreed on the reasoning, with one qualification.

Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a chromatogram included. Submission is by mail.

VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing about what is in a container.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.

Worth separating two things that post #2 runs together.

Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and selective reporting. The extra effort is worth it.

This follows post #4 rather than contradicting it.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity, labelling, shipping. Following their instructions exactly ensures results are interpretable.

Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.

When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.

On post #9 — agreed on the reasoning, with one qualification.

Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies reproducibility but uses the same method.

post #13 answers the question as asked. The question underneath it is different.

PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over time rather than at a point in time.